Relationship Between Gene Expression of 5-Fluorouracil Metabolic Enzymes and 5-Fluorouracil Sensitivity in Primary Cancer Cells Isolated from Malignant Ascites

REFERENCES

• Ohtsu A. Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 2005;8:95–102.
   PubMedGoogle Scholar
• Toriumi F, Kubota T, Saikawa Y, Yoshida M, Otani Y, Watanabe M, Kumai K, Kitajima M. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA levels as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res 2004;24:2455–2463.
   PubMed Web of Science ®Google Scholar
• Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987;47:2203–2206.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5’-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986;46:20–28.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M, Kitajima M. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 2000;91:105–112.
   PubMedGoogle Scholar
• Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003;9:786–791.
   PubMed Web of Science ®Google Scholar
• Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y, Hirayama R. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003;89:1486–1492.
   PubMed Web of Science ®Google Scholar
• Ochiai T, Nishimura K, Noguchi H, Kitajima M, Tsukada A, Watanabe E, Nagaoka I, Futagawa S. Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer 2006;118: 3084–3088.
   PubMed Web of Science ®Google Scholar
• Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 2002;3:75–82.
   Google Scholar
• Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifl uridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685–690.
   PubMed Web of Science ®Google Scholar
• Neale MH, Lamont A, Hindley A, Kurbacher CM, Cree IA. The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma. Anticancer Drugs 2000;11:865–871.
   PubMed Web of Science ®Google Scholar
• Konstantinovsky S, Nielsen S, Vyberg M, Kvalheim G, Nesland JM, Reich R, Davidson B. Angiogenic molecule expression is downregulated in effusions from breast cancer patients. Breast Cancer Res 2005;94:71–80.
   Web of Science ®Google Scholar
• Kuramochi H, Hayashi K, Uchida K, Nakajima G, Hatori T, Danenberg KD, Danenberg PV, Yamamoto M. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. Cancer Chemother Pharmacol 2008;63:85–89.
   PubMed Web of Science ®Google Scholar
• Takechi T, Fujioka A, Matsushima E, Fukushima M. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 2000;38:1271–1277.
   Web of Science ®Google Scholar
• Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995;1: 305–311.
   PubMed Web of Science ®Google Scholar
• Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H, Nagura H, Ogawa N, HoVman RM. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1995;1: 1537–1543.
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fuorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;5:330–338.
   Google Scholar
• Kuniyasu T, Nakamura T, Tabuchi Y, Kuroda Y. Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 1998;7:1300–1306.
   Google Scholar
• Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002;20:1721–1728.
   PubMed Web of Science ®Google Scholar
• Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi OP, Pitt HA, Ahrendt SA. Thymidylate synthase expression predicts the response to 5-fluorouracilbased adjuvant therapy in pancreatic cancer. Clin Cancer Res 2003;9:4165–4171.
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Wada H, Ogawa O, Yoshida O, Fukushima M, Nonomura N, Miki T. Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 2001;92:510–518.
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O'Connell MJ, Levitt R, Kugler JW, Tria Tirona M, Goldberg RM. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002;20:1735–1743.
   PubMed Web of Science ®Google Scholar
• Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F, Sobrero A. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999;17:1760–1770.
   PubMed Web of Science ®Google Scholar
• Kanai F, Kawakami T, Hamada H, Sadata A, Yoshida Y, Tanaka T, Ohashi M, Tateishi K, Shiratori Y, Omata M. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998;58:1946–1951.
   PubMed Web of Science ®Google Scholar
• Inaba M, Sawada H, Sadata A, Hamada H. Circumvention of 5-fluorouracil resistance in human stomach cancer cells by uracil phosphoribosyltransferase gene transduction. Jpn J Cancer Res 1999;90:349–354.
   PubMedGoogle Scholar
• Terashima M, Fujiwara H, Takagane A, Abe K, Araya M, Irinoda T, Yonezawa H, Nakaya T, Oyama K, Takahashi M, Saito K. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifl uridine in gastric cancer patients. Eur J Cancer 2002;38:2375–2381.
   PubMed Web of Science ®Google Scholar
• Konno S, Takebayashi Y, Aiba M, Akiyama S, Oqawa K. Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma. Cancer Lett 2001;166:103–111.
   PubMed Web of Science ®Google Scholar
• Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, Sasaki Y, Hirayama R. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 2006;119:1927–1933.
   PubMed Web of Science ®Google Scholar